Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

INmune Bio: An Opportunity In The Freefall (Rating Upgrade) [Seeking Alpha]

INmune Bio Inc. - Common stock (INMB) 
Company Research Source: Seeking Alpha
The company's most advanced product candidate is XPro 1595, which is being developed for Alzheimer's disease. INMB's financial situation may require a cash raise by the end of 2024, but there is potential for significant upside if their clinical platforms show positive results. Topline Summary and Update INmune Bio ( NASDAQ: INMB ) is a company focused on developing drugs in two different disease areas: neurology and cancer medicine. I've previously covered this company in two articles, and I was a cautious optimist Recommended For You Recommended For You About INMB Stock Show less Read more
Impact Snapshot
Event Time:
INMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
INMB alerts

from News Quantified
Opt-in for
INMB alerts

from News Quantified